NOW ENROLLING: ATLAS CLINICAL TRIAL FOR UNCONTROLLED ASTHMA

HELP PATIENTS ACCESS AN INVESTIGATIONAL TREATMENT AIMED AT PREVENTING LUNG FUNCTION DECLINE.

About the Study

LPS16676 – ATLAS Study | Sponsored by Sanofi
The ATLAS trial is a Phase 4, randomized, double-blind, placebo-controlled clinical trial evaluating whether dupilumab, when added to standard asthma medications, can help prevent or slow lung function decline in adults with uncontrolled moderate to severe asthma. Dupilumab is already FDA-approved for several type 2 inflammatory conditions. This 3-year study will further assess its long-term benefits in asthma care.

ClinicalTrials.gov ID: NCT05097287

WHY REFER A PATIENT

Patients remain on their standard asthma medications
3-year study designed to generate valuable, longitudinal data
Close clinical monitoring and communication with referring physicians
Patients return to your care after participation
Advance care for asthma patients at risk of progressive lung decline

ELIGIBILITY SNAPSHOT*

Key Inclusion Criteria:

Age ≥18 years with asthma diagnosis for ≥1 year
Treatment with medium or high dose Inhaled corticosteroids + second controller ± third controller on a stable dose for ≥1 month prior to the screening visit
Pre-bronchodilator FEV1 ≤80% predicted normal
Uncontrolled asthma (ACQ-5 ≥1.5) • ≥1 severe asthma exacerbation in the past year

Key Exclusion Criteria:

History or clinical evidence of COPD
Current smoker or cessation of smoking within 6 months prior to study initiation
Severe Asthma exacerbation requiring systemic corticosteroids in the last 4 weeks prior to study initiation
Treatment with live (attenuated) vaccine within 4 weeks before study initiation
Any biologic therapy (including experimental treatments and dupilumab) within 4 weeks or 5 half-lives prior to study initiation

*The Temple Lung Center is seeking to screen patients who meet the above main criteria, but this list is not exhaustive

STUDY DESIGN

Key Inclusion Criteria:

Duration: 3 years
Intervention: Dupilumab or placebo + standard of care (ICS + controller meds)
Rescue algorithm in place for poorly controlled patients

Evaluation of:

Lung function Exacerbation frequency
Patient-reported outcomes
Biomarker trends

Temple Lung Center: A Center of Research Excellence

The Temple Lung Center is actively enrolling in more than 50 clinical trials at any given time, focused on improving diagnosis, care, and outcomes for patients with both common and complex lung diseases. Our physician-researchers have been at the forefront of groundbreaking studies, offering new hope to patients locally and from across the U.S.

REFER A PATIENT

Principal Investigator: Kartik Shenoy, MD, Temple Lung Center

215-707-1359

[email protected]

We appreciate your partnership in bringing forward better options for patients with uncontrolled asthma

Schedule an appointment